{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T06:37:12Z","timestamp":1791959832853,"version":"4.3.4"},"reference-count":52,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2021,3,27]],"date-time":"2021-03-27T00:00:00Z","timestamp":1616803200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100013030","name":"William and Ella Owens Medical Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013030","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["movementdisorders.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Movement Disorders"],"published-print":{"date-parts":[[2021,8]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Neuroinflammation plays a key role in PD pathogenesis, and allogeneic bone marrow\u2013derived mesenchymal stem cells can be used as an immunomodulatory therapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>The objective of this study was to prove the safety and tolerability of intravenous allogeneic bone marrow\u2013derived mesenchymal stem cells in PD patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This was a 12\u2010month single\u2010center open\u2010label dose\u2010escalation phase 1 study of 20 subjects with mild\/moderate PD assigned to a single intravenous infusion of 1 of 4 doses: 1, 3, 6, or 10\u2009\u00d7\u200910<jats:sup>6<\/jats:sup> allogeneic bone marrow\u2013derived mesenchymal stem cells\/kg, evaluated 3, 12, 24, and 52\u2009weeks postinfusion. Primary outcome safety measures included transfusion reaction, study\u2010related adverse events, and immunogenic responses. Secondary outcomes included impact on peripheral markers, PD progression, and changes in brain perfusion.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>There were no serious adverse reactions related to the infusion and no responses to donor\u2010specific human leukocyte antigens. Most common treatment\u2010emergent adverse events were dyskinesias (20%, n\u00a0=\u00a04) with 1 emergent and 3 exacerbations; and hypertension (20%, n\u00a0=\u00a04) with 3 transient episodes and 1 requiring medical intervention. One possibly related serious adverse event occurred in a patient with a 4\u2010year history of lymphocytosis who developed asymptomatic chronic lymphocytic leukemia. Peripheral inflammation markers appear to be reduced at 52\u2009weeks in the highest dose including, tumor necrosis factor\u2010\u03b1 (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.05), chemokine (C\u2010C motif) ligand 22 (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.05), whereas brain\u2010derived neurotrophic factor (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.05) increased. The highest dose seems to have demonstrated the most significant effect at 52\u2009weeks, reducing the OFF state UPDRS motor, \u221214.4 (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.01), and total, \u221220.8 (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.05), scores.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>A single intravenous infusion of allogeneic bone marrow\u2013derived mesenchymal stem cells at doses of 1, 3, 6, or 10\u2009\u00d7\u200910<jats:sup>6<\/jats:sup> allogeneic bone marrow\u2013derived mesenchymal stem cells\/kg is safe, well tolerated, and not immunogenic in mild\/moderate PD patients. \u00a9 2021 The Authors. <jats:italic>Movement Disorders<\/jats:italic> published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society<\/jats:p><\/jats:sec>","DOI":"10.1002\/mds.28582","type":"journal-article","created":{"date-parts":[[2021,3,27]],"date-time":"2021-03-27T07:47:45Z","timestamp":1616831265000},"page":"1825-1834","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":63,"title":["Allogeneic Bone Marrow\u2013Derived Mesenchymal Stem Cell Safety in Idiopathic Parkinson's Disease"],"prefix":"10.1002","volume":"36","author":[{"given":"Mya","family":"Schiess","sequence":"first","affiliation":[{"name":"Department of Neurology, McGovern Medical School University of Texas Health Science Center at Houston  Houston Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessika","family":"Suescun","sequence":"additional","affiliation":[{"name":"Department of Neurology, McGovern Medical School University of Texas Health Science Center at Houston  Houston Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie\u2010Francoise","family":"Doursout","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, McGovern Medical School University of Texas Health Science Center at Houston  Houston Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Adams","sequence":"additional","affiliation":[{"name":"Department of Neurology, McGovern Medical School University of Texas Health Science Center at Houston  Houston Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Green","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, McGovern Medical School University of Texas Health Science Center at Houston  Houston Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerome G.","family":"Saltarrelli","sequence":"additional","affiliation":[{"name":"Department of Surgery, McGovern Medical School University of Texas Health Science Center at Houston  Houston Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"Savitz","sequence":"additional","affiliation":[{"name":"Department of Neurology, McGovern Medical School University of Texas Health Science Center at Houston  Houston Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy M.","family":"Ellmore","sequence":"additional","affiliation":[{"name":"Department of Psychology The City College of New York  New York City New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,3,27]]},"reference":[{"issue":"1","key":"e_1_2_9_2_1","first-page":"1003","article-title":"Neuroinflammation induces neurodegeneration","volume":"1","author":"Kempuraj D","year":"2016","journal-title":"J Neurol Neurosurg Spine"},{"key":"e_1_2_9_3_1","first-page":"143","article-title":"Cytokines in Parkinson's disease","volume":"58","author":"Nagatsu T","year":"2000","journal-title":"J Neural Transm Suppl"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0301-0082(02)00127-2"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2005.08.002"},{"issue":"1","key":"e_1_2_9_6_1","first-page":"182","article-title":"Infiltration of CD4+ lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease","volume":"119","author":"Brochard V","year":"2009","journal-title":"J Clin Invest"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11481-009-9176-0"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(09)70062-6"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.20682"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3181d5a4a3"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1089\/jir.2012.0088"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.2174\/1874205X01610010067"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2202-11-151"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.brainres.2008.03.081"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0052285"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1159\/000460297"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neulet.2014.10.039"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.retram.2016.10.007"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1089\/scd.2015.0127"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-4159.2008.05589.x"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.3727\/096368909X470801"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.brainres.2007.09.086"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2013.11.001"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.3727\/096368911X582769c"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2013.06.021"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-013-1399-4"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1378\/chest.12-2094"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0047559"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1093\/gerona\/glx056"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2014.01.417"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.dib.2017.04.013"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1006\/cbmr.1996.0014"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroimage.2020.117031"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1177\/0115426505020003314"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcb.1174"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.clpt.6100386"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1186\/1479-5876-12-14"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(11)70305-2"},{"issue":"4","key":"e_1_2_9_39_1","first-page":"592","article-title":"Safety, feasibility of intravenous and intrathecal injection of autologous bone marrow derived mesenchymal stromal cells in patients with amyotrophic lateral sclerosis: an open label phase I clinical trial","volume":"20","author":"Nabavi SM","year":"2019","journal-title":"Cell J"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-020-04240-9"},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4939-3584-0_7"},{"key":"e_1_2_9_42_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2016.2742"},{"key":"e_1_2_9_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jocn.2019.01.017"},{"key":"e_1_2_9_44_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-014-1345-4"},{"key":"e_1_2_9_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbi.2008.07.003"},{"key":"e_1_2_9_46_1","doi-asserted-by":"publisher","DOI":"10.1002\/glia.20731"},{"key":"e_1_2_9_47_1","doi-asserted-by":"publisher","DOI":"10.1096\/fj.05-5106com"},{"key":"e_1_2_9_48_1","doi-asserted-by":"publisher","DOI":"10.1002\/sctm.19-0010"},{"key":"e_1_2_9_49_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000008620"},{"key":"e_1_2_9_50_1","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2019.00134"},{"key":"e_1_2_9_51_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2014.391"},{"key":"e_1_2_9_52_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.20914"},{"key":"e_1_2_9_53_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.21894"}],"container-title":["Movement Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mds.28582","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/mds.28582","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mds.28582","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T11:40:41Z","timestamp":1760960441000},"score":1,"resource":{"primary":{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/10.1002\/mds.28582"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,27]]},"references-count":52,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["10.1002\/mds.28582"],"URL":"https:\/\/doi.org\/10.1002\/mds.28582","archive":["Portico"],"relation":{},"ISSN":["0885-3185","1531-8257"],"issn-type":[{"value":"0885-3185","type":"print"},{"value":"1531-8257","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,27]]},"assertion":[{"value":"2020-09-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-03-02","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-03-27","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}